{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:50:59Z","timestamp":1790769059753,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["CoG 614739"],"award-info":[{"award-number":["CoG 614739"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13071-017-2293-3","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T10:16:16Z","timestamp":1501582576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium"],"prefix":"10.1186","volume":"10","author":[{"given":"Jana","family":"Kova\u010d","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,1]]},"reference":[{"issue":"7","key":"2293_CR1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(06)70521-7","volume":"6","author":"P Steinmann","year":"2006","unstructured":"Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6(7):411\u201325.","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"2293_CR2","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1017\/S0031182009991600","volume":"136","author":"J Utzinger","year":"2009","unstructured":"Utzinger J, Raso G, Brooker S, De Savigny D, Tanner M, Ornbjerg N, et al. Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology. 2009;136(13):1859\u201374.","journal-title":"Parasitology"},{"issue":"9936","key":"2293_CR3","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(13)61949-2","volume":"383","author":"DG Colley","year":"2014","unstructured":"Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014;383(9936):2253\u201364.","journal-title":"Lancet"},{"issue":"9541","key":"2293_CR4","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0140-6736(06)69440-3","volume":"368","author":"B Gryseels","year":"2006","unstructured":"Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. 2006;368(9541):1106\u201318.","journal-title":"Lancet"},{"issue":"1","key":"2293_CR5","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s13071-014-0478-6","volume":"7","author":"HAHA Ismail","year":"2014","unstructured":"Ismail HAHA, Hong S-T, Babiker ATEB, Hassan RMAE, Sulaiman MAZ, Jeong H-G, et al. Prevalence, risk factors, and clinical manifestations of schistosomiasis among school children in the White Nile River basin. Sudan Parasit Vectors. 2014;7(1):478.","journal-title":"Sudan Parasit Vectors"},{"issue":"16","key":"2293_CR6","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1056\/NEJMra012396","volume":"346","author":"AGP Ross","year":"2002","unstructured":"Ross AGP, Bartley PB, Sleigh AC, Olds GR, Li Y, Williams GM, et al. Schistosomiasis; Current concepts. N Engl J Med. 2002;346(16):1212\u201320.","journal-title":"N Engl J Med"},{"key":"2293_CR7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1742395307084407","volume":"4","author":"CH King","year":"2008","unstructured":"King CH, Dangerfield-cha M. The unacknowledged impact of chronic schistosomiasis. Chronic Illn. 2008;4:65\u201379.","journal-title":"Chronic Illn"},{"key":"2293_CR8","doi-asserted-by":"crossref","unstructured":"Bustinduy AL, Wright S, Joekes EC, Kabatereine NB, Reinhard-Rupp J, King CH, et al. One hundred years of neglect in paediatric schistosomiasis. Parasitology. 2017:1\u201311.","DOI":"10.1017\/S0031182017000014"},{"issue":"1","key":"2293_CR9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.molbiopara.2014.06.002","volume":"195","author":"D Cioli","year":"2014","unstructured":"Cioli D, Pica-Mattoccia L, Basso A, Guidi A. Schistosomiasis control: Praziquantel forever? Mol Biochem Parasitol. 2014;195(1):23\u20139.","journal-title":"Mol Biochem Parasitol"},{"issue":"10","key":"2293_CR10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0065-308X(10)73008-6","volume":"73","author":"J Keiser","year":"2010","unstructured":"Keiser J, Utzinger J. The drugs we have and the drugs we need against major helminth infections. Adv Parasitol. 2010;73(10):197\u2013230.","journal-title":"Adv Parasitol"},{"key":"2293_CR11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/jac\/dkt491","volume":"69","author":"P Olliaro","year":"2014","unstructured":"Olliaro P, Delgado-Romero P, Keiser J. The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). J Antimicrob Chemother. 2014;69:863\u201370.","journal-title":"J Antimicrob Chemother"},{"key":"2293_CR12","first-page":"263","volume":"5","author":"J Utzinger","year":"2004","unstructured":"Utzinger J, Keiser J. Schistosomiasis and soil- transmitted helminthiasis: common drugs for treatment and control. Expert Opin Drug Discov. 2004;5:263\u201385.","journal-title":"Expert Opin Drug Discov"},{"issue":"6","key":"2293_CR13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/QCO.0b013e328359f04a","volume":"25","author":"TG Geary","year":"2012","unstructured":"Geary TG. Are new anthelmintics needed to eliminate human helminthiases? Curr Opin Infect Dis. 2012;25(6):709\u201317.","journal-title":"Curr Opin Infect Dis"},{"key":"2293_CR14","doi-asserted-by":"publisher","unstructured":"Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Ibrahim N, Wynn NB, et al. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis. 2009;3(8) doi:\n10.1371\/journal.pntd.0000504\n\n.","DOI":"10.1371\/journal.pntd.0000504"},{"key":"2293_CR15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0020-7519(01)00246-6","volume":"31","author":"Y Liang","year":"2001","unstructured":"Liang Y, Coles GC, Doenhoff MJ, Southgate VR. In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel. Int J Parasitol. 2001;31:1227\u201335.","journal-title":"Int J Parasitol"},{"issue":"6","key":"2293_CR16","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/infdis\/151.6.1130","volume":"151","author":"SH Xiao","year":"1985","unstructured":"Xiao SH, Catto BA, Webster LTJ. Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis. 1985;151(6):1130\u20137.","journal-title":"J Infect Dis"},{"key":"2293_CR17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF01951341","volume":"58","author":"CJ Chavasse","year":"1979","unstructured":"Chavasse CJ, Brown MC, Bell DR. Schistosoma mansoni: Activity responses in vitro to praziquantel. Z Parasitenkd. 1979;58:169\u201374.","journal-title":"Z Parasitenkd."},{"key":"2293_CR18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00389901","volume":"52","author":"G Webbe","year":"1977","unstructured":"Webbe G, James C. A comparison of the susceptibility to praziquantel of Schistosoma haematobium, S. japonicum, S. mansoni, S. intercalatum and S. mattheei in hamsters. Z Parasitenkd. 1977;52:169\u201377.","journal-title":"Z Parasitenkd"},{"issue":"2","key":"2293_CR19","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1645\/GE-1270.1","volume":"94","author":"SS Botros","year":"2008","unstructured":"Botros SS, Hammam OA, El-Lakkani NM, El-Din SH, Ebeid FA. Schistosoma haematobium (Egyptian strain): rate of development and effect of praziquantel treatment. J Parasitol. 2008;94(2):386\u201394.","journal-title":"J Parasitol"},{"key":"2293_CR20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijpara.2003.12.003","volume":"34","author":"L Pica-Mattoccia","year":"2004","unstructured":"Pica-Mattoccia L, Cioli D. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol. 2004;34:527\u201333.","journal-title":"Int J Parasitol"},{"issue":"2","key":"2293_CR21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4269\/ajtmh.1989.41.198","volume":"41","author":"M Tanaka","year":"1989","unstructured":"Tanaka M, Ohmae H, Utsunomiya H, Nara T, Irie Y, Yasuraoka K. A comparison of the antischistosomal effect of levo- and dextro- praziquantel on Schistosoma japonicum and S. mansoni in mice. Am J Trop Med Hyg. 1989;41(2):198\u2013203.","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"2293_CR22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/infdis\/159.3.589","volume":"159","author":"SH Xiao","year":"1989","unstructured":"Xiao SH, Catto BA. Comparative in vitro and in vivo activity of racemic praziquantel and its levorotated isomer on Schistosoma mansoni. J Infect Dis. 1989;159(3):589\u201392.","journal-title":"J Infect Dis"},{"key":"2293_CR23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0035-9203(99)90039-1","volume":"93","author":"SH Xiao","year":"1999","unstructured":"Xiao SH, Chollet J, Booth M, Weiss NA, Tanner M. Therapeutic effect of praziquantel enantiomers in mice infected with Schistosoma mansoni. Trans R Soc Trop Med Hyg. 1999;93:324\u20135.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2293_CR24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/BF00931694","volume":"78","author":"U Staudt","year":"1992","unstructured":"Staudt U, Schmahl G, Blaschke G, Mehlhorn H. Light and scanning electron microscopy studies on the effects of the enantiomers of praziquantel and its main metabolite on Schistosoma mansoni in vitro. Parasitol Res. 1992;78:392\u20137.","journal-title":"Parasitol Res"},{"issue":"2","key":"2293_CR25","first-page":"241","volume":"77","author":"SH Xiao","year":"1991","unstructured":"Xiao SH, You JQ, Guo HF, Catto BA. Uptake and effect of praziquantel and the major human oxidative metabolite, 4-hydroxypraziquantel, by Schistosoma japonicum. J Infect Dis. 1991;77(2):241\u20135.","journal-title":"J Infect Dis"},{"key":"2293_CR26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1017\/S0031182009991739","volume":"137","author":"J Keiser","year":"2010","unstructured":"Keiser J. In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology. 2010;137:589\u2013603.","journal-title":"Parasitology"},{"issue":"4","key":"2293_CR27","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2307\/3273883","volume":"40","author":"DV Moore","year":"1954","unstructured":"Moore DV, Meleney HE. Comparative susceptibility of common laboratory animals to experimental infection with Schistosoma haematobium. J Parasitol. 1954;40(4):392\u20137.","journal-title":"J Parasitol"},{"key":"2293_CR28","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1017\/S0031182009000493","volume":"136","author":"MJ Doenhoff","year":"2009","unstructured":"Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, Botros S, et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology. 2009;136:1825\u201335.","journal-title":"Parasitology"},{"key":"2293_CR29","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.ijpara.2005.05.002","volume":"35","author":"S Botros","year":"2005","unstructured":"Botros S, Pica-Mattoccia L, William S, El-Lakkani N, Cioli D. Effect of praziquantel on the immature stages of Schistosoma haematobium. Int J Parasitol. 2005;35:1453\u20137.","journal-title":"Int J Parasitol"},{"issue":"11","key":"2293_CR30","doi-asserted-by":"crossref","first-page":"e3286","DOI":"10.1371\/journal.pntd.0003286","volume":"8","author":"J Zwang","year":"2014","unstructured":"Zwang J, Olliaro PL. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis - a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis. 2014;8(11):e3286.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"2293_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpara.2009.11.001","volume":"40","author":"TG Geary","year":"2010","unstructured":"Geary TG, Woo K, McCarthy JS, Mackenzie CD, Horton J, Prichard RK, et al. Unresolved issues in anthelmintic pharmacology for helminthiases of humans. Int J Parasitol. 2010;40(1):1\u201313.","journal-title":"Int J Parasitol"},{"issue":"6","key":"2293_CR32","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/QCO.0b013e328318978f","volume":"21","author":"MJ Doenhoff","year":"2008","unstructured":"Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008;21(6):659\u201367.","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"2293_CR33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1371\/journal.pntd.0000357","volume":"3","author":"T Meyer","year":"2009","unstructured":"Meyer T, Sekljic H, Fuchs S, Bothe H, Schollmeyer D, Miculka C. Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment. PLoS Negl Trop Dis. 2009;3(1):3\u20137.","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"2293_CR34","doi-asserted-by":"crossref","first-page":"e00227","DOI":"10.1128\/mBio.00227-16","volume":"7","author":"AL Bustinduy","year":"2016","unstructured":"Bustinduy AL, Waterhouse D, de Sousa-Figueiredo JC, Roberts SA, Atuhaire A, Van Dam GJ, et al. Population pharmacokinetics and pharmacodynamics of praziquantel in Ugandan children with intestinal schistosomiasis: higher dosages are required for maximal efficacy. MBio. 2016;7(4):e00227\u201316.","journal-title":"MBio"},{"issue":"4","key":"2293_CR35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pt.2013.02.001","volume":"29","author":"M Betson","year":"2013","unstructured":"Betson M, Stothard JR, Bustinduy A, Reinhard-rupp J. Schistosomiasis in African infants and preschool children : let them now be treated! Trends Parasitol. 2013;29(4):197\u2013205.","journal-title":"Trends Parasitol"},{"issue":"9","key":"2293_CR36","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1128\/AAC.02741-14","volume":"58","author":"I Meister","year":"2014","unstructured":"Meister I, Ingram-Sieber K, Cowan N, Todd M, Robertson MN, Meli C, et al. Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni. Antimicrob Agents Chemother. 2014;58(9):5466\u201372.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Parasites & Vectors"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-017-2293-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T10:16:37Z","timestamp":1501582597000},"score":1,"resource":{"primary":{"URL":"http:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-017-2293-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2293"],"URL":"https:\/\/doi.org\/10.1186\/s13071-017-2293-3","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,1]]},"article-number":"365"}}